These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 32919178)

  • 21. Risk Factors for Bleeding in Cancer Patients Treated with Conventional Dose Followed by Low-Dose Apixaban for Venous Thromboembolism.
    Hussaini P; Larsen TL; Ghanima W; Dahm AEA
    Thromb Haemost; 2024 Apr; 124(4):351-362. PubMed ID: 37816388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of Direct-Acting Oral Anticoagulant Use in Patients With Cancer.
    Davis DO; Davis KA
    J Pharm Pract; 2018 Oct; 31(5):441-444. PubMed ID: 28803521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apixaban in Japanese patients with cancer-associated venous thromboembolism: a multi-center phase II trial.
    Imamura Y; Otsui K; Mori K; Kitagawa K; Okada H; Hata A; Hayashi H; Nose T; Ohata S; Miyata Y; Funakoshi Y; Toyoda M; Yakushijin K; Kiyota N; Matsuoka H; Minami H
    Int J Hematol; 2022 Apr; 115(4):499-507. PubMed ID: 35079961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial.
    Becattini C; Bauersachs R; Maraziti G; Bertoletti L; Cohen A; Connors JM; Manfellotto D; Sanchez A; Brenner B; Agnelli G
    Haematologica; 2022 Jul; 107(7):1567-1576. PubMed ID: 34382385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and Effectiveness of Direct Oral Anticoagulants for the Treatment of Gastrointestinal Cancer-Associated Venous Thromboembolism.
    Ullah F; Song J; Rojas Hernandez CM; Kroll MH; Escalante CP; Toale KM
    Oncologist; 2023 Nov; 28(11):e1005-e1016. PubMed ID: 37310796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multi-center retrospective study evaluating the efficacy and safety of apixaban versus warfarin for treatment of venous thromboembolism in patients with severe obesity.
    Crouch A; Ng TH; Kelley D; Knight T; Edwin S; ; Giuliano C
    Pharmacotherapy; 2022 Feb; 42(2):119-133. PubMed ID: 34904263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.
    Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Terleira-Fernández AI; Vargas-Castrillón E
    Vasc Health Risk Manag; 2014; 10():627-39. PubMed ID: 25404858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population.
    Hlavacek P; Guo JD; Rosenblatt L; Keshishian A; Russ C; Mardekian J; Ferri M; Poretta T; Yuce H; McBane R
    Curr Med Res Opin; 2019 Dec; 35(12):2043-2051. PubMed ID: 31387467
    [No Abstract]   [Full Text] [Related]  

  • 29. Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.
    Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
    Clin Ther; 2016 Mar; 38(3):478-93.e1-16. PubMed ID: 26922297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of direct oral anticoagulants for the treatment of venous thromboembolism in the oncology population.
    Hedvat J; Howlett C; McCloskey J; Patel R
    J Thromb Thrombolysis; 2018 Nov; 46(4):483-487. PubMed ID: 30191357
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Apixaban and Rivaroxaban in Patients With Acute Venous Thromboembolism.
    Bott-Kitslaar DM; McBane RD; Casanegra AI; Houghton DE; Froehling DA; Vlazny DT; Ashrani AA; Hodge DO; Vargas ER; Bartlett MA; Saadiq RA; Daniels PR; Shields RC; Lenz CJ; Lang TR; Wysokinski WE
    Mayo Clin Proc; 2019 Jul; 94(7):1242-1252. PubMed ID: 30737059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral apixaban for the treatment of acute venous thromboembolism.
    Agnelli G; Buller HR; Cohen A; Curto M; Gallus AS; Johnson M; Masiukiewicz U; Pak R; Thompson J; Raskob GE; Weitz JI;
    N Engl J Med; 2013 Aug; 369(9):799-808. PubMed ID: 23808982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of effectiveness and safety for low versus full dose of apixaban during extended phase oral anticoagulation in patients with venous thromboembolism.
    DeRemer CE; Dietrich EA; Kang HR; Huang PL; Lo-Ciganic WH; Park H
    J Intern Med; 2022 Jun; 291(6):877-885. PubMed ID: 35192737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial.
    McBane RD; Wysokinski WE; Le-Rademacher JG; Zemla T; Ashrani A; Tafur A; Perepu U; Anderson D; Gundabolu K; Kuzma C; Perez Botero J; Leon Ferre RA; Henkin S; Lenz CJ; Houghton DE; Vishnu P; Loprinzi CL
    J Thromb Haemost; 2020 Feb; 18(2):411-421. PubMed ID: 31630479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis.
    Dawwas GK; Brown J; Dietrich E; Park H
    Lancet Haematol; 2019 Jan; 6(1):e20-e28. PubMed ID: 30558988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.
    van Es N; Coppens M; Schulman S; Middeldorp S; Büller HR
    Blood; 2014 Sep; 124(12):1968-75. PubMed ID: 24963045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of direct oral anticoagulants compared to low-molecular-weight-heparins for treatment of cancer associated venous thromboembolism in Spain.
    Muñoz A; Gallardo E; Agnelli G; Crespo C; Forghani M; Arumi D; Fernández de Cabo S; Soto J
    J Med Econ; 2022; 25(1):840-847. PubMed ID: 35703036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis.
    Arce-Huamani MA; Barboza JJ; Martínez-Herrera JF; Torres-Roman JS; Maguiña JL
    Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893585
    [No Abstract]   [Full Text] [Related]  

  • 39. Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada.
    Quon P; Le HH; Raymond V; Mtibaa M; Moshyk A
    J Med Econ; 2016 Jun; 19(6):557-67. PubMed ID: 26761644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
    Cohen AT; Hamilton M; Bird A; Mitchell SA; Li S; Horblyuk R; Batson S
    PLoS One; 2016; 11(8):e0160064. PubMed ID: 27487187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.